Ultra Market Research | North America Obesity Drugs Market
North America Obesity Drugs Market
Report ID : 786
Category : Pharmaceuticals,North-America
No Of Pages : 154
Published on: October 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
North America Obesity Drugs Market
Introduction
The North America obesity drugs market has witnessed significant growth, driven by the increasing prevalence of obesity and associated health conditions such as diabetes, cardiovascular diseases, and hypertension. Obesity treatment drugs, commonly known as weight loss drugs, are used in the pharmacological management of obesity, targeting the reduction of body weight and fat levels in patients who do not respond to traditional weight management strategies. The market comprises a range of prescription medications that aid in weight management, including appetite suppressants, fat absorption inhibitors, and GLP-1 receptor agonists. The market size for obesity drugs in North America is substantial, with projections indicating continuous growth due to rising awareness and healthcare expenditure on obesity management. Increasing acceptance of prescription weight loss drugs and obesity medication innovation is shaping the future of the North America weight loss market, further boosted by positive anti-obesity drug forecasts in 2024 and beyond.
Segmentation
By Drug Type
Appetite Suppressants
Anorexiants
Serotonin Receptor Agonists
Others
Fat Absorption Inhibitors
Lipase Inhibitors
Other Enzyme Inhibitors
GLP-1 Receptor Agonists
Short-acting GLP-1 Agonists
Long-acting GLP-1 Agonists
Others
Combination Drugs
Herbal and Nutraceutical Formulations
By Application
Clinical Obesity Treatment
Severe Obesity
Morbid Obesity
Others
Lifestyle Weight Management
Overweight but not Obese
Weight Maintenance Post-Loss
Pediatric Obesity Treatment
Childhood Obesity Interventions
Adolescent Obesity Solutions
Others
Geriatric Obesity Management
Cardiovascular Focused Treatments
Endocrine and Hormonal Therapies
Others
By Distribution Channel
Hospitals
Public Hospitals
Private Hospitals
Specialized Treatment Centers
Retail Pharmacies
Chain Pharmacies
Independent Pharmacies
Online Pharmacies
Telehealth Platforms
Direct-to-Consumer Platforms
By Route of Administration
Oral Administration
Tablets
Capsules
Others
Injectable Administration
Intramuscular
Subcutaneous
Transdermal Patches
Slow Release
Rapid Absorption
List of Market Players
Novo Nordisk (Denmark) Pfizer Inc. (United States) Roche Holding AG (Switzerland) AstraZeneca (United Kingdom) GlaxoSmithKline plc (United Kingdom) Allergan plc (Ireland) Eli Lilly and Company (United States) Boehringer Ingelheim (Germany) Johnson & Johnson (United States) Takeda Pharmaceuticals (Japan) Arena Pharmaceuticals (United States) Vivus, Inc. (United States) Orexigen Therapeutics (United States) Zafgen Inc. (United States) Acerus Pharmaceuticals Corporation (Canada)
Drivers
Rising obesity rates are driving demand for effective pharmacological interventions, particularly given the limitations of traditional diet and exercise regimens in managing severe obesity.
The increasing acceptance of weight loss drugs among patients and healthcare providers is bolstered by supportive clinical data and new, less invasive drug delivery options.
Advancements in obesity pharmaceuticals, especially GLP-1 receptor agonists, are offering more effective weight management outcomes.
Growing awareness of obesity-related comorbidities, such as Type 2 diabetes and cardiovascular disease, encourages early intervention through medications.
The presence of major players in North America with substantial R&D investments is accelerating new product developments and boosting market growth.
Increasing healthcare expenditure in the U.S. and Canada, coupled with insurance coverage for weight management treatments, supports accessibility to prescription obesity drugs.
Restraints
The high cost of obesity medications limits access, particularly for uninsured or underinsured populations, affecting market penetration in some segments.
Side effects associated with long-term use of weight loss drugs, such as cardiovascular or gastrointestinal issues, can lead to caution among patients and healthcare providers.
Regulatory hurdles and lengthy approval processes for new obesity drugs challenge rapid market entry, with strict safety and efficacy standards.
Social stigma around obesity medications and a preference for non-pharmacological weight management methods hinder patient uptake in certain demographics.
Limited success in achieving long-term weight loss with pharmacotherapy alone highlights the need for a comprehensive, multidisciplinary approach, limiting drug dependency.
Generic competition and the expiration of patents on key obesity drugs introduce pricing pressures and challenge revenue growth for brand-name medications.
Opportunity
Expansion into untapped markets in Canada and rural areas of the U.S. offers new revenue streams as healthcare infrastructure develops in these regions.
Innovation in obesity treatment drugs, particularly those targeting specific hormones or neural pathways, offers novel therapeutic options and expands the market.
Increasing use of telemedicine and online pharmacies provides greater access to obesity medications, especially in underserved areas, fueling market expansion.
Collaborative efforts between pharmaceutical companies and weight management clinics provide patients with holistic weight management solutions, increasing treatment adherence.
Rising demand for personalized medicine in obesity management creates opportunities for precision drugs based on genetic, lifestyle, and metabolic factors.
Partnerships with insurance companies to cover obesity medications in health plans can make these drugs more accessible, boosting market growth and drug adoption rates.
Trend
A dominant trend in the North America obesity drugs market is the shift toward personalized, evidence-based treatments designed to target individual patient profiles. Advances in pharmacogenetics and metabolic research are enabling a tailored approach to obesity drugs, where medications are prescribed based on patients’ unique genetic and metabolic makeup. GLP-1 receptor agonists are particularly notable, as they offer dual benefits for both diabetes and obesity, providing a strategic advantage for patients dealing with comorbid conditions. Additionally, the integration of digital health technologies, including mobile apps and wearable devices, supports patients in managing their weight, adhering to drug regimens, and tracking progress. Remote monitoring facilitated by telemedicine is also becoming more prevalent, allowing healthcare providers to offer continuous support and adjust treatments as needed. This trend emphasizes a comprehensive approach, combining pharmacotherapy with digital tools for long-term obesity management, appealing to a tech-savvy patient base increasingly willing to embrace novel healthcare solutions.
Key Target Audience
Hospitals and Weight Loss Clinics Obesity and Metabolic Health Specialists Retail and Online Pharmacies Insurance Providers and Health Plan Administrators Pharmaceutical Manufacturers and Distributors Government Health Agencies Research Institutes and Academia
FAQs about the North America Obesity Drugs Market
The North America obesity drugs market consists of prescription drugs used to aid weight loss and manage obesity.
Increasing obesity prevalence, innovative drug treatments, and rising healthcare expenditure drive demand in this market.
Availability is growing, but costs and insurance coverage impact access, particularly in lower-income areas.
Common drugs include appetite suppressants, fat absorption inhibitors, and GLP-1 receptor agonists.
Trends include personalized treatments, GLP-1 drugs, and the integration of telemedicine and digital health tools.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis 2. Market Dashboard 3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Drug Type 3.2.2 By Application 3.2.3 By Distribution Channel 3.2.4 By Route of Administration 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges 4. North America Obesity Drugs Market by Drug Type 4.1 Introduction 4.2 Market Size and Growth Rate by Drug Type (2024-2030) 4.2.1 Appetite Suppressants 4.2.1.1 Anorexiants 4.2.1.2 Serotonin Receptor Agonists 4.2.1.3 Others 4.2.2 Fat Absorption Inhibitors 4.2.2.1 Lipase Inhibitors 4.2.2.2 Other Enzyme Inhibitors 4.2.3 GLP-1 Receptor Agonists 4.2.3.1 Short-acting GLP-1 Agonists 4.2.3.2 Long-acting GLP-1 Agonists 4.2.3.3 Others 4.2.4 Combination Drugs 4.2.5 Herbal and Nutraceutical Formulations 5. North America Obesity Drugs Market by Application 5.1 Introduction 5.2 Market Size and Growth Rate by Application (2024-2030) 5.2.1 Clinical Obesity Treatment 5.2.1.1 Severe Obesity 5.2.1.2 Morbid Obesity 5.2.1.3 Others 5.2.2 Lifestyle Weight Management 5.2.2.1 Overweight but not Obese 5.2.2.2 Weight Maintenance Post-Loss 5.2.3 Pediatric Obesity Treatment 5.2.3.1 Childhood Obesity Interventions 5.2.3.2 Adolescent Obesity Solutions 5.2.3.3 Others 5.2.4 Geriatric Obesity Management 5.2.4.1 Cardiovascular Focused Treatments 5.2.4.2 Endocrine and Hormonal Therapies 5.2.4.3 Others 6. North America Obesity Drugs Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospitals 6.2.1.1 Public Hospitals 6.2.1.2 Private Hospitals 6.2.1.3 Specialized Treatment Centers 6.2.2 Retail Pharmacies 6.2.2.1 Chain Pharmacies 6.2.2.2 Independent Pharmacies 6.2.3 Online Pharmacies 6.2.3.1 Telehealth Platforms 6.2.3.2 Direct-to-Consumer Platforms 7. North America Obesity Drugs Market by Route of Administration 7.1 Introduction 7.2 Market Size and Growth Rate by Route of Administration (2024-2030) 7.2.1 Oral Administration 7.2.1.1 Tablets 7.2.1.2 Capsules 7.2.1.3 Others 7.2.2 Injectable Administration 7.2.2.1 Intramuscular 7.2.2.2 Subcutaneous 7.2.3 Transdermal Patches 7.2.3.1 Slow Release 7.2.3.2 Rapid Absorption 8. Competitive Landscape 8.1 Company Profiles 8.1.1 Novo Nordisk (Denmark) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Pfizer Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.3 Roche Holding AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.4 AstraZeneca (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.5 GlaxoSmithKline plc (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.6 Allergan plc (Ireland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.7 Eli Lilly and Company (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.8 Boehringer Ingelheim (Germany) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.9 Johnson & Johnson (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.10 Takeda Pharmaceuticals (Japan) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.11 Arena Pharmaceuticals (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.12 Vivus, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.13 Orexigen Therapeutics (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.14 Zafgen Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.15 Acerus Pharmaceuticals Corporation (Canada) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9. List of Tables and Figures List of Tables Table North America Obesity Drugs Market Size by Drug Type (2024-2030) Table Appetite Suppressants Market Size by Sub-type (2024-2030) Table Fat Absorption Inhibitors Market Size by Sub-type (2024-2030) Table GLP-1 Receptor Agonists Market Size by Sub-type (2024-2030) Table Combination Drugs Market Size (2024-2030) Table Herbal and Nutraceutical Formulations Market Size (2024-2030) Table North America Obesity Drugs Market Size by Application (2024-2030) Table Clinical Obesity Treatment Market Size by Sub-type (2024-2030) Table Lifestyle Weight Management Market Size by Sub-type (2024-2030) Table Pediatric Obesity Treatment Market Size by Sub-type (2024-2030) Table Geriatric Obesity Management Market Size by Sub-type (2024-2030) Table North America Obesity Drugs Market Size by Distribution Channel (2024-2030) Table Hospitals Market Size by Sub-type (2024-2030) Table Retail Pharmacies Market Size by Sub-type (2024-2030) Table Online Pharmacies Market Size by Sub-type (2024-2030) Table North America Obesity Drugs Market Size by Route of Administration (2024-2030) Table Oral Administration Market Size by Sub-type (2024-2030) Table Injectable Administration Market Size by Sub-type (2024-2030) Table Transdermal Patches Market Size by Sub-type (2024-2030) List of Figures Figure North America Obesity Drugs Market Size and Growth Rate by Drug Type (2024-2030) Figure Appetite Suppressants Market Growth Rate by Sub-type (2024-2030) Figure Fat Absorption Inhibitors Market Growth Rate by Sub-type (2024-2030) Figure GLP-1 Receptor Agonists Market Growth Rate by Sub-type (2024-2030) Figure Combination Drugs Market Growth Rate (2024-2030) Figure Herbal and Nutraceutical Formulations Market Growth Rate (2024-2030) Figure North America Obesity Drugs Market Size and Growth Rate by Application (2024-2030) Figure Clinical Obesity Treatment Market Growth Rate by Sub-type (2024-2030) Figure Lifestyle Weight Management Market Growth Rate by Sub-type (2024-2030) Figure Pediatric Obesity Treatment Market Growth Rate by Sub-type (2024-2030) Figure Geriatric Obesity Management Market Growth Rate by Sub-type (2024-2030) Figure North America Obesity Drugs Market Size and Growth Rate by Distribution Channel (2024-2030) Figure Hospitals Market Growth Rate by Sub-type (2024-2030) Figure Retail Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Online Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure North America Obesity Drugs Market Size and Growth Rate by Route of Administration (2024-2030) Figure Oral Administration Market Growth Rate by Sub-type (2024-2030) Figure Injectable Administration Market Growth Rate by Sub-type (2024-2030) Figure Transdermal Patches Market Growth Rate by Sub-type (2024-2030)
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macroeconomic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of North America market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of North America Obesity Drugs Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue North Americaly. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of North America Obesity Drugs Market for the past year and forecasts for the next six years. North America North America Obesity Drugs Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different North America Obesity Drugs Market Market categories. Market size and forecasts for each major application is provided in the context of North America market. The numbers provided in this report are derived on the basis of demand for North America Obesity Drugs Market from different application industries in different regions.
